Introduction - The prevalence of sexual dysfunctions has increased over the last decades; despite a number of available treatments for erectile dysfunction (ED), premature ejaculation (PE) and Peyronie's disease (PD), still several unmet therapeutic needs deserve to be fulfilled. The aim of this review is to detail on phase I and II clinical trials investigating novel medical treatments for ED, PE and PD. Areas covered - We conducted a systematic review of the literature including both published and on-going phase I and II registered trials focused on medical treatment of ED, PE and PD during the last 5 years. A total of 35 trials have been identified. Most studies (63%) investigated ED treatments and 26% were still on-going. Stem cells (SCs) therapy was assessed in 28% of trials. Expert opinion - SCs therapy represent a promising treatment for ED although only few patients have been treated to date. Likewise, the oral selective oxytocin receptor antagonists for treating PE showed excellent safety profile and deserve further investigations in phase III trials. Preliminary results of novel topical treatments for PD with fibrinolytic and anti-inflammatory drugs are encouraging, but urgently need to be confirmed in large placebo-controlled trials.
Expert opinion on investigational drugs. 2018 Jul 03 [Epub ahead of print]
Paolo Capogrosso, Francesco Montorsi, Andrea Salonia
a Università Vita-Salute San Raffaele , Milan , Italy.